Unknown

Dataset Information

0

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.


ABSTRACT:

Introduction

Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer's disease (AD). We aimed to compare six P-tau Simoa assays, including three P-tau181 (Eli Lilly, ADx, Quanterix), one P-tau217 (Eli Lilly), and two P-tau231 (ADx, Gothenburg).

Methods

We studied the analytical (sensitivity, precision, parallelism, dilution linearity, and recovery) and clinical (40 AD dementia patients, age 66±8years, 50%F; 40 age- and sex-matched controls) performance of the assays.

Results

All assays showed robust analytical performance, and particularly P-tau217 Eli Lilly; P-tau231 Gothenburg and all P-tau181 assays showed robust clinical performance to differentiate AD from controls, with AUCs 0.936-0.995 (P-tau231 ADx: AUC = 0.719). Results obtained with all P-tau181 assays, P-tau217 Eli Lilly assay, and P-tau231 Gothenburg assay strongly correlated (Spearman's rho > 0.86), while correlations with P-tau231 ADx results were moderate (rho < 0.65).

Discussion

P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays.

SUBMITTER: Bayoumy S 

PROVIDER: S-EPMC8645090 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8605616 | biostudies-literature
| S-EPMC9999575 | biostudies-literature
| S-EPMC9499867 | biostudies-literature
| S-EPMC8451860 | biostudies-literature
| S-EPMC8609462 | biostudies-literature
| S-EPMC7653537 | biostudies-literature
| S-EPMC7125218 | biostudies-literature
| S-EPMC8590691 | biostudies-literature
| S-EPMC9800279 | biostudies-literature
| S-EPMC8734209 | biostudies-literature